Christopher J.H. Porter

List of Publications by Year in Descending Order

252 papers	17,616 citations	73 h-index	125 g-index
260 ext. papers	19,367 ext. citations	7.2 avg, IF	6.8 L-index

#	Paper	IF	Citations
252	Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport.. *Frontiers in Pharmacology*, **2022**, 13, 879660	5.6	
251	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.. *Journal of Controlled Release*, **2021**, 341, 676-701	11.7	1
250	Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation. *European Journal of Pharmaceutics and Biopharmaceutics*, **2021**,	5.7	1
249	Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability. *Molecular Pharmaceutics*, **2021**, 18, 1768-1778	5.6	2
248	Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat. *International Journal of Pharmaceutics*, **2021**, 596, 120247	6.5	2
247	Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs. *Journal of Controlled Release*, **2021**, 331, 45-61	11.7	1
246	Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations. *International Journal of Pharmaceutics*, **2021**, 597, 120292	6.5	1
245	Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. *Journal of Controlled Release*, **2021**, 332, 636-651	11.7	6
244	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. *Advanced Drug Delivery Reviews*, **2021**, 171, 289-331	18.5	30
243	Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. *Pharmaceutical Research*, **2021**, 38, 1125-1137	4.5	3
242	Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass Cytometry. *ACS Applied Materials & Interfaces*, **2021**, 13, 35494-35505	9.5	2
241	The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. *Journal of Pharmaceutical Sciences*, **2021**, 110, 489-499	3.9	6
240	A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes. *Journal of Biological Chemistry*, **2021**, 296, 100345	5.4	3
239	Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. *Nanomedicine*, **2021**, 16, 275-292	5.6	3
238	Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune and Neoral Lipid-Based Formulations. *Pharmaceutical Research*, **2021**, 38, 1531-1547	4.5	
237	Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. *Nature Metabolism*, **2021**, 3, 1175-1188	14.6	17
236	High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration. *Molecular Pharmaceutics*, **2020**, 17, 2938-2951	5.6	4

235	Targeting immune cells within lymph nodes. *Nature Nanotechnology*, **2020**, 15, 423-425	28.7	12
234	Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans. *Frontiers in Physiology*, **2020**, 11, 458	4.6	14
233	Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition. *American Journal of Physiology - Renal Physiology*, **2020**, 318, G725-G735	5.1	7
232	Spatial Properties of Reactive Oxygen Species Govern Pathogen-Specific Immune System Responses. *Antioxidants and Redox Signaling*, **2020**, 32, 982-992	8.4	12
231	Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations. *Pharmaceutical Research*, **2020**, 37, 47	4.5	6
230	API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility.. *RSC Advances*, **2020**, 10, 12788-12799	3.7	5
229	Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. *Advanced Drug Delivery Reviews*, **2020**, 160, 115-135	18.5	7
228	A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor agonists. *Journal of Biological Chemistry*, **2019**, 294, 3720-3734	5.4	7
227	Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms. *Advanced Drug Delivery Reviews*, **2019**, 142, 75-90	18.5	26
226	A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 137, 218-226	5.7	7
225	The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*, **2019**, 134, 31-59	5.1	119
224	Engineering Biocoatings To Prolong Drug Release from Supraparticles. *Biomacromolecules*, **2019**, 20, 3425-3434	6.9	11
223	Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties. *Molecular Pharmaceutics*, **2019**, 16, 4987-4999	5.6	15
222	Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. *Journal of Controlled Release*, **2019**, 315, 85-96	11.7	5
221	Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. *Pharmaceutics*, **2019**, 12,	6.4	14
220	Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency. *Nano Letters*, **2019**, 19, 1827-1831	11.5	24
219	A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL. *Journal of Pharmaceutical Sciences*, **2019**, 108, 193-204	3.9	15
218	Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation. *Journal of Controlled Release*, **2019**, 296, 29-39	11.7	10

217	Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation. *Molecular Pharmaceutics*, **2018**, 15, 2355-2371	5.6	27
216	Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels. *Journal of Neurochemistry*, **2018**, 146, 186-197	6	5
215	Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption. *Pharmaceutical Research*, **2018**, 35, 55	4.5	34
214	Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells. *Journal of Pharmaceutical Sciences*, **2018**, 107, 1185-1193	3.9	12
213	Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution. *Biomaterials*, **2018**, 178, 570-582	15.6	34
212	Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations. *Journal of Pharmaceutical Sciences*, **2018**, 107, 203-216	3.9	23
211	Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E7438-E7447	11.5	78
210	Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. *Journal of Pharmaceutical Sciences*, **2018**, 107, 2509-2513	3.9	11
209	Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations. *Molecular Pharmaceutics*, **2018**, 15, 4733-4744	5.6	23
208	Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. *Molecular Pharmaceutics*, **2018**, 15, 4568-4576	5.6	29
207	Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets. *Journal of Neurochemistry*, **2018**, 144, 81-92	6	12
206	Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. *Molecular Pharmaceutics*, **2018**, 15, 5678-5696	5.6	24
205	Minimum information reporting in bio-nano experimental literature. *Nature Nanotechnology*, **2018**, 13, 777-785	28.7	297
204	Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery. *ACS Applied Materials & Interfaces*, **2018**, 10, 31019-31031	9.5	20
203	Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids. *Molecular Pharmaceutics*, **2017**, 14, 566-579	5.6	23
202	Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief. *Science Translational Medicine*, **2017**, 9,	17.5	91
201	Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods. *Molecular Pharmaceutics*, **2017**, 14, 394-405	5.6	13
200	Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion. *Molecular Pharmaceutics*, **2017**, 14, 580-592	5.6	24

199	Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 12309-12314	11.5	83
198	Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution. *ACS Applied Materials & Interfaces*, **2017**, 9, 33683-33694	9.5	15
197	Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies. *Molecular Pharmaceutics*, **2017**, 14, 3669-3683	5.6	35
196	Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. *European Journal of Pharmaceutics and Biopharmaceutics*, **2017**, 119, 408-418	5.7	22
195	An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. *Biomacromolecules*, **2017**, 18, 2866-2875	6.9	12
194	Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2017**, 13, 2485-2494	6	16
193	Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623. *Molecular Pharmaceutics*, **2017**, 14, 4525-4538	5.6	12
192	Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. *Nature Communications*, **2017**, 8, 69	17.4	75
191	Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids. *Molecular Pharmaceutics*, **2017**, 14, 3684-3697	5.6	22
190	Fatty Acid-Binding Protein 5 at the Blood-Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function. *Journal of Neuroscience*, **2016**, 36, 11755-11767	6.6	44
189	Frontispiece: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie - International Edition*, **2016**, 55,	16.4	1
188	Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug. *Journal of Pharmaceutical Sciences*, **2016**, 105, 786-796	3.9	13
187	Tools for Early Prediction of Drug Loading in Lipid-Based Formulations. *Molecular Pharmaceutics*, **2016**, 13, 251-61	5.6	52
186	A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. *Pharmaceutical Research*, **2016**, 33, 510-25	4.5	20
185	Conjugation of 10 kDa Linear PEG onto Trastuzumab FabSIs Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. *Molecular Pharmaceutics*, **2016**, 13, 1229-41	5.6	22
184	The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. *Journal of Pharmaceutical Sciences*, **2016**, 105, 293-300	3.9	15
183	Computational prediction of formulation strategies for beyond-rule-of-5 compounds. *Advanced Drug Delivery Reviews*, **2016**, 101, 6-21	18.5	92
182	A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations. *Pharmaceutical Research*, **2016**, 33, 970-82	4.5	46

181	Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts. *Chemical Communications*, **2016**, 52, 9121-4	5.8	21
180	50years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, **2016**, 101, 167-194	18.5	229
179	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. *Molecular Pharmaceutics*, **2016**, 13, 1904-14	5.6	20
178	Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. *Pharmaceutical Research*, **2016**, 33, 2920-2929	4.5	8
177	Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs. *Molecular Pharmaceutics*, **2016**, 13, 3351-3361	5.6	28
176	Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie - International Edition*, **2016**, 55, 13700-13705	16.4	38
175	Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie*, **2016**, 128, 13904-13909	3.6	3
174	Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations. *Molecular Pharmaceutics*, **2015**, 12, 1980-91	5.6	101
173	Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug. *Pharmaceutical Research*, **2015**, 32, 1830-44	4.5	24
172	Fatty Acid-Binding Protein 5 Facilitates the Blood-Brain Barrier Transport of Docosahexaenoic Acid. *Molecular Pharmaceutics*, **2015**, 12, 4375-85	5.6	63
171	From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. *Nature Reviews Drug Discovery*, **2015**, 14, 781-803	64.1	336
170	Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. *Pharmaceutical Research*, **2015**, 32, 3432-46	4.5	8
169	Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2015**, 11, 2099-108	6	15
168	Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase. *Pharmaceutical Research*, **2015**, 32, 1279-87	4.5	49
167	Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration. *Journal of Pharmaceutical Sciences*, **2015**, 104, 1421-30	3.9	14
166	The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport. *Journal of Visualized Experiments*, **2015**,	1.6	17
165	Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor in a Ligand-selective Manner. *Journal of Biological Chemistry*, **2015**, 290, 13895-906	5.4	37
164	Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases. *Molecular Pharmaceutics*, **2015**, 12, 4424-33	5.6	26

163	Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats. *Molecular Pharmaceutics*, **2015**, 12, 432-43	5.6	41
162	PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. *Molecular Pharmaceutics*, **2015**, 12, 794-809	5.6	28
161	Size and rigidity of cylindrical polymer brushes dictate long circulating properties in vivo. *ACS Nano*, **2015**, 9, 1294-304	16.7	110
160	Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion. *Pharmaceutical Research*, **2014**, 31, 1536-52	4.5	8
159	Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. *Journal of Controlled Release*, **2014**, 183, 18-26	11.7	130
158	Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. *Journal of Controlled Release*, **2014**, 193, 241-56	11.7	77
157	The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol. *Journal of Pharmacy and Pharmacology*, **2014**, 66, 1377-87	4.8	4
156	The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. *Molecular Pharmaceutics*, **2014**, 11, 496-504	5.6	36
155	Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein. *ACS Chemical Biology*, **2014**, 9, 2526-34	4.9	13
154	An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations. *Molecular Pharmaceutics*, **2014**, 11, 4069-83	5.6	25
153	Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1050-63	3.9	14
152	Stealth lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. *Journal of Controlled Release*, **2014**, 192, 219-27	11.7	54
151	Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components. *Molecular Pharmaceutics*, **2014**, 11, 2825-34	5.6	34
150	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. *Journal of Pharmaceutical Sciences*, **2014**, 103, 2441-55	3.9	36
149	Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2570-9	5.9	115
148	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels. *AAPS Journal*, **2014**, 16, 1344-57	3.7	45
147	In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 88, 973-85	5.7	12
146	Ionic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility. *Chemical Communications*, **2014**, 50, 1688-90	5.8	93

145	Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1734-46	3.9	39
144	Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. *Journal of Controlled Release*, **2014**, 177, 1-10	11.7	57
143	Dendrimers for Biomedical Applications. *Frontiers in Nanobiomedical Research*, **2014**, 279-328		
142	Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. *Pharmaceutical Research*, **2013**, 30, 2976-92	4.5	79
141	Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles. *Pharmaceutical Research*, **2013**, 30, 3045-58	4.5	40
140	Computational prediction of drug solubility in lipid based formulation excipients. *Pharmaceutical Research*, **2013**, 30, 3225-37	4.5	74
139	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations. *Pharmaceutical Research*, **2013**, 30, 3059-76	4.5	78
138	A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport. *Pharmaceutical Research*, **2013**, 30, 3254-70	4.5	28
137	Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. *Molecular Pharmaceutics*, **2013**, 10, 2986-95	5.6	81
136	The impact of lymphatic transport on the systemic disposition of lipophilic drugs. *Journal of Pharmaceutical Sciences*, **2013**, 102, 2395-408	3.9	23
135	A simple quantitative approach for the determination of long and medium chain lipids in bio-relevant matrices by high performance liquid chromatography with refractive index detection. *AAPS PharmSciTech*, **2013**, 14, 927-34	3.9	17
134	In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine. *European Journal of Pharmaceutical Sciences*, **2013**, 49, 748-60	5.1	32
133	Strategies to address low drug solubility in discovery and development. *Pharmacological Reviews*, **2013**, 65, 315-499	22.5	992
132	In vitro digestion testing of lipid-based delivery systems: calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products. *International Journal of Pharmaceutics*, **2013**, 441, 323-33	6.5	91
131	Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5087-95	5.9	38
130	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. *Journal of Controlled Release*, **2013**, 172, 128-136	11.7	61
129	The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug. *Journal of Pharmaceutical Sciences*, **2013**, 102, 565-78	3.9	36
128	PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. *Journal of Controlled Release*, **2013**, 168, 200-8	11.7	58

127	Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component analysis. *Molecular Pharmaceutics*, **2013**, 10, 2823-48	5.6	44
126	The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs. *Molecular Pharmaceutics*, **2013**, 10, 2601-15	5.6	33
125	Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. *Journal of Controlled Release*, **2013**, 167, 85-91	11.7	38
124	Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. *Molecular Pharmaceutics*, **2013**, 10, 1874-89	5.6	58
123	Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats. *Journal of Pharmaceutical Sciences*, **2013**, 102, 3957-65	3.9	9
122	A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2012**, 8, 103-11	6	132
121	Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. *Molecular Pharmaceutics*, **2012**, 9, 3286-300	5.6	97
120	Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier. *Molecular Pharmaceutics*, **2012**, 9, 2750-60	5.6	64
119	Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. *Molecular Pharmaceutics*, **2012**, 9, 2063-79	5.6	109
118	Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. *Molecular Pharmaceutics*, **2012**, 9, 422-32	5.6	59
117	Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. *Molecular Pharmaceutics*, **2012**, 9, 355-73	5.6	110
116	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. *Journal of Pharmaceutical Sciences*, **2012**, 101, 3360-80	3.9	185
115	Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies. *Journal of Pharmaceutical Sciences*, **2012**, 101, 3540-6	3.9	12
114	Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. *Nanomedicine*, **2011**, 6, 1063-84	5.6	145
113	Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. *Journal of Controlled Release*, **2011**, 152, 241-8	11.7	107
112	Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. *Journal of Controlled Release*, **2011**, 153, 180-6	11.7	147
111	Targeting the lymphatics using dendritic polymers (dendrimers). *Advanced Drug Delivery Reviews*, **2011**, 63, 890-900	18.5	92
110	Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?. *Pharmaceutical Research*, **2011**, 28, 2176-90	4.5	11

109	Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration. *Drug Delivery and Translational Research*, **2011**, 1, 429-38	6.2	26
108	Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 291-5		3
107	Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. *Journal of Pharmaceutical Sciences*, **2011**, 100, 5069-77	3.9	56
106	Capping methotrexate γ-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. *Molecular Pharmaceutics*, **2011**, 8, 338-49	5.6	53
105	Correction to "targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?". *Molecular Pharmaceutics*, **2011**, 8, 2484	5.6	4
104	Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption. *Molecular Pharmaceutics*, **2011**, 8, 1132-9	5.6	4
103	Structure activity relationship of dendrimer microbicides with dual action antiviral activity. *PLoS ONE*, **2010**, 5, e12309	3.7	120
102	Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. *Journal of Drug Targeting*, **2010**, 18, 704-31	5.4	242
101	Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?. *Molecular Pharmaceutics*, **2010**, 7, 2297-309	5.6	36
100	An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. *Journal of Pharmacy and Pharmacology*, **2010**, 60, 1311-1319	4.8	12
99	Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media. *Journal of Pharmacy and Pharmacology*, **2010**, 62, 844-855	4.8	46
98	Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. *Journal of Pharmacy and Pharmacology*, **2010**, 62, 856-865	4.8	57
97	The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). *Pharmaceutical Research*, **2010**, 27, 878-93	4.5	31
96	The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. *Pharmaceutical Research*, **2010**, 27, 1949-64	4.5	31
95	Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 331, 700-9	4.7	17
94	Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. *Current Drug Delivery*, **2009**, 6, 359-66	3.2	13
93	PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. *Journal of Controlled Release*, **2009**, 140, 108-16	11.7	110
92	Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. *Molecular and Cellular Biochemistry*, **2009**, 326, 87-95	4.2	16

91	Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. *Pharmaceutical Research*, **2009**, 26, 1486-95	4.5	37
90	Probing the fibrate binding specificity of rat liver fatty acid binding protein. *Journal of Medicinal Chemistry*, **2009**, 52, 5344-55	8.3	14
89	Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. *Molecular Pharmaceutics*, **2009**, 6, 1190-204	5.6	122
88	The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. *Molecular Pharmaceutics*, **2008**, 5, 449-63	5.6	151
87	Characterization of the drug binding specificity of rat liver fatty acid binding protein. *Journal of Medicinal Chemistry*, **2008**, 51, 3755-64	8.3	55
86	Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2008**, 97, 209-24	3.9	11
85	Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. *Journal of Pharmaceutical Sciences*, **2008**, 97, 995-1012	3.9	133
84	Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. *Advanced Drug Delivery Reviews*, **2008**, 60, 702-16	18.5	302
83	Lipid-based systems for the enhanced delivery of poorly water soluble drugs. *Advanced Drug Delivery Reviews*, **2008**, 60, 615-6	18.5	83
82	Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. *Advanced Drug Delivery Reviews*, **2008**, 60, 625-37	18.5	581
81	Enhancing intestinal drug solubilisation using lipid-based delivery systems. *Advanced Drug Delivery Reviews*, **2008**, 60, 673-91	18.5	515
80	An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. *Journal of Pharmacy and Pharmacology*, **2008**, 60, 1311-9	4.8	8
79	Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2007**, 96, 280-93	3.9	42
78	Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. *Chemistry and Biology*, **2007**, 14, 453-65		28
77	A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. *International Journal of Pharmaceutics*, **2007**, 340, 52-60	6.5	140
76	Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, **2007**, 6, 231-48	64.1	1252
75	Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. *Pharmaceutical Research*, **2007**, 24, 748-57	4.5	125
74	Low dose lipid formulations: effects on gastric emptying and biliary secretion. *Pharmaceutical Research*, **2007**, 24, 2084-96	4.5	85

73	Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. *Drug Metabolism and Disposition*, **2007**, 35, 2211-7	4	55
72	Lymphatic Absorption of Orally Administered Prodrugs **2007**, 653-682		5
71	Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. *Molecular Pharmaceutics*, **2007**, 4, 949-61	5.6	47
70	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. *PLoS Medicine*, **2007**, 4, e335	11.6	137
69	Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. *Journal of Pharmacy and Pharmacology*, **2006**, 58, 809-20	4.8	58
68	Tissue uptake of DDT is independent of chylomicron metabolism. *Archives of Toxicology*, **2006**, 80, 196-200	3.8	9
67	Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols. *European Journal of Lipid Science and Technology*, **2006**, 108, 714-722	3	6
66	Permeability assessment of poorly water-soluble compounds under solubilizing conditions: the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2006**, 95, 2170-85	3.9	46
65	The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 881-91	4.7	39
64	An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. *Drug Metabolism and Disposition*, **2006**, 34, 729-33	4	32
63	Lipid-based Systems, Drug Exposure and Lead Optimization **2006**, 131-150		
62	Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. *Molecular Pharmaceutics*, **2006**, 3, 614-27	5.6	134
61	An acute and coincident increase in FABP expression and lymphatic lipid and drug transport occurs during intestinal infusion of lipid-based drug formulations to rats. *Pharmaceutical Research*, **2006**, 23, 1786-96	4.5	7
60	The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. *Pharmaceutical Research*, **2006**, 23, 2060-6	4.5	32
59	The interaction of lipophilic drugs with intestinal fatty acid-binding protein. *Journal of Biological Chemistry*, **2005**, 280, 17769-76	5.4	46
58	An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli. *Protein Expression and Purification*, **2005**, 44, 23-31	2	11
57	Subcutaneous drug delivery and the role of the lymphatics. *Drug Discovery Today: Technologies*, **2005**, 2, 89-96	7.1	141
56	Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. *Journal of Controlled Release*, **2005**, 107, 523-36	11.7	14

55	Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. *Journal of Pharmaceutical Sciences*, **2005**, 94, 481-92	3.9	81
54	Bile increases intestinal lymphatic drug transport in the fasted rat. *Pharmaceutical Research*, **2005**, 22, 1863-70	4.5	38
53	Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 345-51	4.7	50
52	Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. *Journal of Pharmacy and Pharmacology*, **2004**, 56, 69-77	4.8	48
51	Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 1085-92	4.7	32
50	Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. *Journal of Controlled Release*, **2004**, 95, 275-89	11.7	6
49	A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs. *Journal of Controlled Release*, **2004**, 99, 217-29	11.7	60
48	Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. *Pharmaceutical Research*, **2004**, 21, 245-53	4.5	160
47	Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. *Pharmaceutical Research*, **2004**, 21, 254-60	4.5	98
46	Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. *Pharmaceutical Research*, **2004**, 21, 1405-12	4.5	197
45	Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. *Journal of Pharmaceutical Sciences*, **2004**, 93, 332-48	3.9	105
44	Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. *Journal of Pharmaceutical Sciences*, **2004**, 93, 1110-21	3.9	179
43	Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo. *Journal of Cardiovascular Pharmacology*, **2003**, 41, 406-13	3.1	11
42	Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. *Pharmaceutical Research*, **2003**, 20, 1156-62	4.5	32
41	Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. *Pharmaceutical Research*, **2003**, 20, 1460-5	4.5	106
40	Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. *European Journal of Pharmaceutical Sciences*, **2003**, 20, 91-7	5.1	110
39	Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. *Journal of Pharmaceutical Sciences*, **2003**, 92, 634-48	3.9	158
38	Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products. *Journal of Pharmaceutical Sciences*, **2003**, 92, 1262-71	3.9	17

37	Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?. *Biopharmaceutics and Drug Disposition*, **2003**, 24, 153-7	1.7	4
36	Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 306, 925-33	4.7	81
35	Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. *Drug Metabolism and Disposition*, **2003**, 31, 1151-60	4	35
34	A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 305, 151-8	4.7	67
33	Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. *Journal of Pharmacy and Pharmacology*, **2002**, 54, 29-41	4.8	231
32	A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. *Journal of Pharmaceutical Sciences*, **2002**, 91, 647-59	3.9	27
31	Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. *Pharmaceutical Research*, **2002**, 19, 1354-61	4.5	53
30	An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. *AAPS PharmSci*, **2002**, 4, E40		143
29	The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. *Journal of Pharmacy and Pharmacology*, **2001**, 53, 1611-9	4.8	40
28	Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. *Journal of Pharmaceutical and Biomedical Analysis*, **2001**, 25, 651-61	3.5	146
27	A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. *Journal of Pharmaceutical Sciences*, **2001**, 90, 1599-607	3.9	82
26	Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. *Pharmaceutical Research*, **2001**, 18, 1620-6	4.5	51
25	Animal models for the study of intestinal lymphatic drug transport. *Advanced Drug Delivery Reviews* , **2001**, 50, 45-60	18.5	84
24	Intestinal lymphatic drug transport: an update. *Advanced Drug Delivery Reviews*, **2001**, 50, 61-80	18.5	276
23	In vitro assessment of oral lipid based formulations. *Advanced Drug Delivery Reviews*, **2001**, 50 Suppl 1, S127-47	18.5	292
22	Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. *Journal of Receptor and Signal Transduction Research*, **2001**, 21, 215-57	2.6	35
21	Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. *Journal of Pharmaceutical Sciences*, **2000**, 89, 168-77	3.9	67
20	Lymphatic transport of proteins after subcutaneous administration. *Journal of Pharmaceutical Sciences*, **2000**, 89, 297-310	3.9	182

19	Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. *Journal of Pharmaceutical Sciences*, **2000**, 89, 1073-84	3.9	214
18	The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. *International Journal of Pharmaceutics*, **2000**, 205, 65-78	6.5	65
17	Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. *Journal of Pharmaceutical Sciences*, **2000**, 89, 168	3.9	53
16	Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. *Journal of Pharmaceutical Sciences*, **1999**, 88, 378-84	3.9	20
15	Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. *Journal of Pharmaceutical Sciences*, **1999**, 88, 185-90	3.9	19
14	Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. *Journal of Pharmaceutical Sciences*, **1998**, 87, 936-42	3.9	52
13	Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. *Journal of Pharmaceutical Sciences*, **1998**, 87, 1538-41	3.9	21
12	Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. *International Journal of Pharmaceutics*, **1998**, 167, 155-164	6.5	277
11	Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. *Journal of Pharmaceutical Sciences*, **1997**, 86, 269-82	3.9	443
10	Uptake of drugs into the intestinal lymphatics after oral administration. *Advanced Drug Delivery Reviews*, **1997**, 25, 71-89	18.5	105
9	Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **1997**, 16, 175-80	3.5	5
8	Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs. *International Journal of Pharmaceutics*, **1996**, 141, 227-237	6.5	23
7	Lipophilic prodrugs designed for intestinal lymphatic transport. *Advanced Drug Delivery Reviews*, **1996**, 19, 149-169	18.5	102
6	Synthesis and evaluation of 5? alkyl ester prodrugs of zidovudine for directed lymphatic delivery. *International Journal of Pharmaceutics*, **1996**, 144, 61-70	6.5	9
5	Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. *Journal of Pharmaceutical Sciences*, **1996**, 85, 351-6	3.9	106
4	Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. *Journal of Pharmaceutical Sciences*, **1996**, 85, 357-61	3.9	57
3	A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. *Journal of Pharmaceutical Sciences*, **1996**, 85, 525-9	3.9	105
2	A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. *Journal of Pharmaceutical and Biomedical Analysis*, **1995**, 13, 265-72	3.5	44

1	The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. *FEBS Letters*, **1992**, 305, 62-6	3.8	136